What question did this study set out to answer?

To evaluate the effectiveness of Elexacaftor/Tezacaftor/Ivacaftor (ETI) on lung function metrics in cystic fibrosis patients.

February 25, 2026Pediatric Pulmonology1 citationsOpen Access

View Full Paper

Respiratory Oscillometry and Multimodal Lung Function Assessment of Elexacaftor/Tezacaftor/Ivacaftor Response in Children and Young Adults With Cystic Fibrosis

CKChristos KogiasAristotle University of Thessaloniki ASAthina SopiadouAristotle University of Thessaloniki SFS FouzasGeneral University Hospital of Patras

Key Points

To evaluate the effectiveness of Elexacaftor/Tezacaftor/Ivacaftor (ETI) on lung function metrics in cystic fibrosis patients.
Analyzed oscillometry parameters before and after ETI treatment.
Included multiple genotype groups for comparison.
Explored the relationship between FOT parameters and other lung function metrics like LCI and spirometry.
Significant improvement in oscillometry parameters observed post-ETI treatment.
Further investigation needed to validate FOT parameters as surrogates for LCI or spirometry.

Abstract

Our preliminary data suggest that oscillometry parameters showed a significant improvement after ETI treatment among all genotype groups. More data are required to assess whether and which FOT parameters could be used as surrogates of LCI or spirometry for the long-term follow-up of pwCF.

AIに質問

Bookmark

View Full Paper

AIに質問

Bookmark

View Full Paper

Respiratory Oscillometry and Multimodal Lung Function Assessment of Elexacaftor/Tezacaftor/Ivacaftor Response in Children and Young Adults With Cystic Fibrosis

Key Points

Abstract

Cite This Study

Also Consider

Also Consider